In the FLAURA trial in which NSCLC patients received osimertinib in first-line treatment, NGS of cfDNA samples did not show any emergence of T790M mutation, as expected by the pharmacodynamics activity of osimertinib, selective for both EGFR-sensitizing and T790M mutations [58]. Here, EGFR is linked to non-small cell lung carcinoma.